Get the Stockscreener App
1.68
6.15%
-0.11
After Hours:
1.66
-0.02
-1.19%
Soligenix Inc stock is traded at $1.68, with a volume of 1.69M.
It is down -6.15% in the last 24 hours and down -39.57% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.79
Open:
$1.77
24h Volume:
1.69M
Relative Volume:
0.16
Market Cap:
$7.20M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.2222
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+21.74%
1M Performance:
-39.57%
6M Performance:
-11.11%
1Y Performance:
-57.89%
1-Day Range:
$1.61
$1.7975
1-Week Range:
$1.325
$1.97
52-Week Range:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.68 | 14.98M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Is Soligenix Inc. (DOA) stock overpriced at current multiplesWeekly Stock Report & Real-Time Sentiment Analysis - newser.com
What machine learning models say about Soligenix Inc.Weekly Investment Report & Entry Point Confirmation Signals - newser.com
Soligenix Inc. stock retracement – recovery analysisJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Applying chart zones and confluence areas to Soligenix Inc.Portfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
Soligenix Expands European Advisory Board to Advance CTCL Treatment Development - citybuzz
Does Soligenix Inc. show high probability of reboundShare Buyback & Growth Focused Stock Pick Reports - newser.com
Will Soligenix Inc. stock recover after recent dropJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
How to manage a losing position in Soligenix Inc.July 2025 Momentum & Short-Term High Return Strategies - newser.com
Soligenix Inc.’s volatility index tracking explainedPortfolio Profit Report & Fast Moving Stock Watchlists - newser.com
Soligenix (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL - Digital Journal
Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates - MarketScreener
EV PD-L1 Decreases in 3 Patients: Aethlon Medical Hemopurifier Shows Early EV, miRNA and T‑cell Changes - Stock Titan
Soligenix Reports Positive Safety Review in Phase 3 CTCL Treatment Trial - citybuzz
Soligenix Stock (SNGX) Opinions on Phase 3 HyBryte™ Safety Milestone - Quiver Quantitative
Soligenix’s Strategic Moves: A Bright Future Ahead? - timothysykes.com
Soligenix shares surge after safety milestone in Phase 3 CTCL trial - MSN
Soligenix stock soars after DMC confirms safety in Phase 3 CTCL study - Investing.com
Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safety Review - GuruFocus
Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial - TipRanks
Soligenix achieves important safety milestone in its confirmatory phase 3 Clinical Trial of HyBryte(TM) for the treatment of cutaneous T-cell lymphoma - MarketScreener
Soligenix reports safety milestone in phase 3 CTCL treatment trial By Investing.com - Investing.com Nigeria
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire
What analysts say about Soligenix Inc DOA stockEarnings Per Share Trends & Learn to Pick Stocks in Under 10 Minutes - earlytimes.in
Has Soligenix Inc. formed a bullish divergence2025 Retail Activity & Verified Entry Point Signals - newser.com
Regression analysis insights on Soligenix Inc. performance2025 Trade Ideas & Weekly Momentum Picks - newser.com
Should you hold or exit Soligenix Inc. nowBear Alert & Verified Swing Trading Watchlists - newser.com
Using AI based signals to follow Soligenix Inc.Weekly Stock Summary & Consistent Income Trade Recommendations - newser.com
Why Soligenix Inc. (DOA0) stock is trending on social media2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Statistical indicators supporting Soligenix Inc.’s strengthWeekly Stock Report & Low Volatility Stock Recommendations - newser.com
Using economic indicators to assess Soligenix Inc. potentialTrade Exit Report & Consistent Profit Trading Strategies - newser.com
Is Soligenix Inc. (DOA) stock a momentum leaderQuarterly Market Review & Daily Price Action Insights - newser.com
Why analysts raise outlook for Soligenix Inc. (DOA0) stockJuly 2025 Macro Moves & Capital Protection Trading Alerts - newser.com
Is Soligenix Inc. stock ready for a breakoutEarnings Growth Summary & Consistent Return Strategy Ideas - newser.com
Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX) - GuruFocus
Can trapped investors hope for a rebound in Soligenix Inc.Day Trade & Daily Profit Focused Screening - newser.com
Why Soligenix Inc. (DOA0) stock remains top ratedJuly 2025 Patterns & Smart Swing Trading Techniques - newser.com
What downside risks could hit Soligenix Inc. (DOA0) stock2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Will Soligenix Inc. stock deliver long term returnsSell Signal & Community Consensus Trade Alerts - newser.com
Will Soligenix Light A New Path In Early-Stage CTCL Treatment With HyBryte? - RTTNews
Soligenix Announces $7.5 Million Public Offering of Common Stock and Warrants - Global Legal Chronicle
Soligenix (NASDAQ: SNGX) Closes $7.5M Public Offering to Extend Cash Runway Through 2026 - Barchart.com
Soligenix Secures $7.5 Million Financing to Advance Rare Disease Treatments Through 2026 - citybuzz
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):